Neurobiology of Aging
Volume 28, Issue 8 , Pages 1215-1220 , August 2007

Impact of the matrix metalloproteinase MMP-3 on dementia

  • Nicole Helbecque

      Affiliations

    • INSERM U744, Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP245, 59019 Lille Cedex, France
    • ,
  • Dominique Cottel

      Affiliations

    • INSERM U744, Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP245, 59019 Lille Cedex, France
    • ,
  • Xavier Hermant

      Affiliations

    • INSERM U744, Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP245, 59019 Lille Cedex, France
    • ,
  • Philippe Amouyel

      Affiliations

    • INSERM U744, Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP245, 59019 Lille Cedex, France
    • Université de Lille 2, CHRU de Lille, Place de Verdun, Lille, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 3 20 87 77 10; fax: +33 3 20 87 78 94.

Received 14 December 2005 ,Revised 24 May 2006 ,Accepted 29 May 2006.

References 

  1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383–421
  2. Amouyel P, Richard F, Cottel D, Amant C, Codron V, Helbecque N. The deletion allele of the angiotensin I converting enzyme gene as a genetic susceptibility factor for cognitive impairment. Neurosci Lett. 1996;217:203–205
  3. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82:239–259
  4. Carson JA, Turner AJ. Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?. J Neurochem. 2002;81:1–8
  5. Corder EH, Ervin JF, Lockhart E, Szymanski MH, Schmechel DE, Hulette CM. Cardiovascular damage in Alzheimer disease: autopsy findings from the bryan ADRC. J Biomed Biotechnol. 2005;2005:189–197
  6. Gnasso A, Motti C, Irace C, Carallo C, Liberatoscioli L, Bernardini S, et al. Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol. 2000;20:1600–1605
  7. Gorelick PB. Risk factors for vascular dementia and Alzheimer disease. Stroke. 2004;35:2620–2622
  8. Helbecque N, Hermant X, Cottel D, Amouyel P. The role of matrix metalloproteinase-9 in dementia. Neurosci Lett. 2003;350:181–183
  9. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study [see comments]. Lancet. 1997;349:151–154
  10. Honig LS, Kukull W, Mayeux R. Atherosclerosis AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology. 2005;64:494–500
  11. Jellinger KA. Pathology and pathophysiology of vascular cognitive impairment. A critical update. Panminerva Med. 2004;46:217–226
  12. Johnston SC, O’Meara ES, Manolio TA, Lefkowitz D, O’Leary DH, Goldstein S, et al. Cognitive impairment and decline are associated with carotid artery disease in patients without clinically evident cerebrovascular disease. Ann Int Med. 2004;140:237–247
  13. Kehoe P, Wavrant-De VF, Crook R, Wu WS, Holmans P, Fenton I, et al. A full genome scan for late onset Alzheimer's disease. Hum Mol Genet. 1999;8:237–245
  14. Lamblin N, Bauters C, Hermant X, Lablanche JM, Helbecque N, Amouyel P. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol. 2002;40:43–48
  15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–944
  16. Mizon-Gerard F, de Groote P, Lamblin N, Hermant X, Dallongeville J, Amouyel P, et al. Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction. Eur Heart J. 2004;25:688–693
  17. Mooser V, Helbecque N, Miklossy J, Marcovina SM, Nicod P, Amouyel P. Interactions between apolipoprotein E and apolipoprotein(a) in patients with late-onset Alzheimer disease. Ann Int Med. 2000;132:533–537
  18. Olson MW, Bernardo MM, Pietila M, Gervasi DC, Toth M, Kotra LP, et al. Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1. J Biol Chem. 2000;275:2661–2668
  19. Pollanen PJ, Karhunen PJ, Mikkelsson J, Laippala P, Perola M, Penttila A, et al. Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloproteinase 9 gene: an autopsy study. Arterioscler Thromb Vasc Biol. 2001;21:1446–1450
  20. Rockman MV, Hahn MW, Soranzo N, Loisel DA, Goldstein DB, Wray GA. Positive selection on MMP3 regulation has shaped heart disease risk. Curr Biol. 2004;14:1531–1539
  21. Roher AE, Kokjohn TA, Beach TG. An association with great implications: vascular pathology and Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20:73–75
  22. Roman GC, Kalaria RN. Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol Aging. 2006;27:1769–1785
  23. Rosenberg GA, Sullivan N, Esiri MM. White matter damage is associated with matrix metalloproteinases in vascular dementia. Stroke. 2001;32:1162–1168
  24. Saarela MS, Lehtimaki T, Rinne JO, Hervonen A, Jylha M, Roytta M, et al. Interaction between matrix metalloproteinase 3 and the epsilon4 allele of apolipoprotein E increases the risk of Alzheimer's disease in Finns. Neurosci Lett. 2004;367:336–339
  25. Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron. 2001;32:177–180
  26. Selkoe DJ. Aging, amyloid, and Alzheimer's disease: a perspective in honor of Carl Cotman. Neurochem Res. 2003;28:1705–1713
  27. Shibata N, Ohnuma T, Higashi S, Usui C, Ohkubo T, Kitajima A, et al. Genetic association between matrix metalloproteinase MMP-9 and MMP-3 polymorphisms and Japanese sporadic Alzheimer's disease. Neurobiol Aging. 2005;26:1011–1014
  28. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-Year longitudinal study of blood pressure and dementia. Lancet. 1996;347:1141–1145
  29. Slooter AJ, van Duijn CM, Bots ML, Ott A, Breteler MB, De Voecht J, et al. Apolipoprotein E genotype, atherosclerosis, and cognitive decline: the Rotterdam Study. J Neural Transm Suppl. 1998;53:17–29
  30. Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, Agnaf OE, et al. Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci. 2005;25:2455–2462
  31. Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol. 2000 Dec;19(7):623–629
  32. Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J. 1995;73:209–215
  33. Yoshiyama Y, Asahina M, Hattori T. Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease brain. Acta Neuropathol (Berl). 2000;99:91–95

PII: S0197-4580(06)00189-8

doi: 10.1016/j.neurobiolaging.2006.05.030

Neurobiology of Aging
Volume 28, Issue 8 , Pages 1215-1220 , August 2007

Article Tools